title: [The possibilities for the rational pharmacotherapy of adenoiditis in the children].
abstract: The available literature data give evidence that viral infection is the main cause underlying the development of inflammatory nasopharyngeal pathology in the children. According to ICD-10, nether acute nor chronic adenoiditis should be considered as a self-consistent nosological entity. Acute adenoiditis is usually regarded as a form of acute nasopharyngitis (J02) or acute respiratory viral infection (J06.9) whereas chronic adenoiditis is commonly referred to as representing other chronic diseases of the tonsils and adenoids (J 35.8). The reactive changes in the nasopharyngeal tonsils begin to be manifested on days 3-5 after the onset of acute respiratory viral infection; thereafter, they persist and gradually disappear within the next 2-3 weeks. In the majority of the cases, acute adenoiditis is actually a physiological reaction of the nasopharyngeal tonsils as the organs of regional mucosal immunity to antigenic stimulation. There is no universally accepted opinion as regards the duration of the inflammatory process which would allow these pathological changes to be considered as turned into chronic ones. This condition is actually not a serious pathology provided it is not associated with the concomitant complications and produces no clinically significant effect on the child's quality of life. Under practical conditions, such children are most frequently treated with the use of irrigation therapy. Taking into account that otorhinolaryngologists all over the world do not consider chronic adenoiditis as an independent nosological entity but distinguish only hypertrophy of adenoid vegetations or chronic rhinosinusitis (in the presence of inflammatory changes in the nasopharynx), it appears correct to speak about chronic adenoiditis provided the clinical manifestations of the disease persist for more than 12 weeks. Based on the predominant etiological component, the viral, bacterial, and allergic forms of nasopharyngeal adenoiditis can be distinguished even though it is rather difficult to actually determine which etiological factor prevails in each concrete case. The aforedescribed situation poses a large number of questions pertaining to the choice of either systemic or topical antibacterial therapy.
authors.affiliation: Russian Medical Academy of Post-Graduate Education, Moscow, Russia, 123242.
authors.forename: E P
authors.initials: EP
authors.lastname: Karpova
authors.affiliation: Russian Medical Academy of Post-Graduate Education, Moscow, Russia, 123242.
authors.forename: D V
authors.initials: DV
authors.lastname: Kharina
mesh_terms: D000234:Adenoids / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D002648:Child; D003907:Dexamethasone / Q000008:administration & dosage*; D004338:Drug Combinations; D016903:Drug Monitoring; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D008297:Male; D014663:Nasal Decongestants / Q000008:administration & dosage; D059085:Nasal Sprays; D009304:Nasopharyngitis / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology / Q000523:psychology; D010656:Phenylephrine / Q000008:administration & dosage*; D011112:Polymyxin B / Q000008:administration & dosage*; D011788:Quality of Life; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D005938:Glucocorticoids; D014663:Nasal Decongestants; D059085:Nasal Sprays; D010656:Phenylephrine; D003907:Dexamethasone; D011112:Polymyxin B